Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
10 August 2020 |
Main ID: |
EUCTR2010-024381-21-BE |
Date of registration:
|
23/09/2011 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
Pediatric patients that received a transplanted kidney will receive immunosuppressive medication-the calcineurin inhibitor (tacrolimus) and antiproliferative agent (MMF)-until they will be randomized between week 4 and 6 to receive either the same treatment or to switch to the investigational drug everolimus. The patients will be followed up until 3 years after transplantation to evaluate the efficacy, tolerability and safety of the treatments and to assess their impact on renal function.
|
Scientific title:
|
A 12-month, multicenter, open label, randomized, controlled study to evaluate the efficacy, tolerability and safety of early introduction of everolimus, reduced CNI, and early steroid elimination compared to standard CNI, mycophenolate mofetil and steroid regimen in paediatric renal transplant recipients with a 24-month additional safety follow-up - not applicable |
Date of first enrolment:
|
01/12/2011 |
Target sample size:
|
106 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-024381-21 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes Randomised: yes Open: yes Single blind: no Double blind: no Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: yes Placebo: no Other: no Number of treatment arms in the trial: 2
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Argentina
|
Belgium
|
France
|
Germany
|
Hungary
|
Italy
|
Norway
|
Spain
|
Sweden
|
United Kingdom
|
United States
| | | | | |
Contacts
|
Name:
|
clinical Trial Information Desk
|
Address:
|
Forum 1, Novartis Campus
4056
Basel
Switzerland |
Telephone:
|
41613241111 |
Email:
|
clinicaltrial.enquiries@novartis.com |
Affiliation:
|
Novartis Pharma AG |
|
Name:
|
clinical Trial Information Desk
|
Address:
|
Forum 1, Novartis Campus
4056
Basel
Switzerland |
Telephone:
|
41613241111 |
Email:
|
clinicaltrial.enquiries@novartis.com |
Affiliation:
|
Novartis Pharma AG |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: Inclusion criteria at baseline (transplantation)
1-Written informed consent/assent must be obtained from the parent(s)
or legal guardian before any assessment is performed.
2- Primary paediatric kidney transplant greater than or equal to 1 year
and younger than 18 years receiving a primary deceased donor or non-
HLA identical living donor (related or unrelated) renal transplant.
Inclusion criteria at randomization (4-6 weeks after transplantation)
1-Patients on TAC + MMF + steroids.
2- Renal function with eGFR > 50 ml/min/1.73 m2 (Schwartz formulaabbreviated). Are the trial subjects under 18? yes Number of subjects for this age range: 106 F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria: exclusion criteria at baseline:
1- Recipients of kidneys from donors with known renal disease (such as
diabetes nephropathy, nephrosclerosis), at the time of transplant.
2 - Recipients of a kidney with a cold ischemia time > 24 hours.
3 - Use of other investigational drugs at the time of enrollment, or within
30 days or 5 half-lives of enrollment, whichever is longer.
4 - History of hypersensitivity or contraindications to any of the study
drugs or to drugs of similar chemical classes, or to any of the excipients.
5 - History of malignancy of any organ system treated or untreated,
within the past 5 years, regardless of whether there is evidence of local
recurrence or metastases.
other protocol-defined exclusion criteria may apply
Exclusion criteria at Randomization (4-6 weeks after transplantation)
1 - Patients with ongoing or currently treated episodes of acute rejection
(any grade) or a steroid resistant acute rejection at the time of
randomization.
2 - Patients who experienced acute cellular rejection (Banff =1B) or any
antibody mediated acute rejection or patients considered at high risk of
antibody mediated acute rejection by the investigator assessment (e.g.
presence of newly formed DSA, histological suspicion) at any time before
randomization (as the DSA quantitative threshold to define high risk is
not fully established, the assessment of the risk will be made after
discussion between the laboratory expert and the investigator who will
take into account all information available and apply best judgment).
3 - Patients with ongoing wound healing problems, clinically significant
wound infection requiring continued therapy or other severe surgical
complication in the opinion of the investigator.
4 - Patients who are treated with drugs that are strong inducers or
inhibitors of cytochrome P450 3A4 (CYP3A4) and can not discontinue the
treatment (see Appendix 6 for list of medications).
5 - Patients with nephrotic range proteinuria (protein to creatinine ratio
=2.0 mg/mg or 200 mg/mmol.
other protocol-defined exclusion criteria may apply
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Therapeutic area: Body processes [G] - Immune system processes [G12]
|
Prevention of acute rejection in paediatric recipients of a renal transplant MedDRA version: 14.1
Level: SOC
Classification code 10038359
Term: Renal and urinary disorders
System Organ Class: 10038359 - Renal and urinary disorders
|
Intervention(s)
|
Trade Name: Certican 0,25 mg tablet Product Name: Certican 0,25 mg Product Code: RAD001 Pharmaceutical Form: Tablet INN or Proposed INN: everolimus CAS Number: 159351-69-6 Current Sponsor code: RAD001 Other descriptive name: EVEROLIMUS Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25-
Trade Name: Certican 0,5 mg tablet Product Name: Certican 0,5 mg Product Code: RAD001 Pharmaceutical Form: Tablet INN or Proposed INN: everolimus CAS Number: 159351-69-6 Current Sponsor code: RAD001 Other descriptive name: EVEROLIMUS Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5-
Trade Name: Certican 0,75 mg tablet Product Name: Certican 0,75 mg Product Code: RAD001 Pharmaceutical Form: Tablet INN or Proposed INN: everolimus CAS Number: 159351-69-6 Current Sponsor code: RAD001 Other descriptive name: EVEROLIMUS Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.75-
Trade Name: Certican 1,0 mg tablet Product Name: Certican 1 mg Product Code: RAD001 Pharmaceutical Form: Tablet INN or Proposed INN: everolimus CAS Number: 159351-69-6 Current Sponsor code: RAD001 Other descriptive name: EVEROLIMUS Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1-
Trade Name: Certican 0,1 mg dispersible tablet Product Name: Certican 0,1 mg Product Code: RAD001 Pharmaceutical Form: Dispersible tablet INN or Proposed INN: everolimus CAS Number: 159351-69-6 Current Sponsor code: RAD001 Other descriptive name: EVEROLIMUS Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.1-
Trade Name: Certican 0,25 mg dsipersible tablet Product Name: Certican 0,25 mg Product Code: RAD001 Pharmaceutical Form: Dispersible tablet INN or Propos
|
Primary Outcome(s)
|
Primary end point(s): 1- The incidence of composite efficacy failure including BPAR, death, and graft loss at 12 months. Local biopsy readings will be used to determine the occurrence of BPAR. 2- Renal function will be assessed by eGFR estimated by the Schwartz formula (abbreviated) at month 12.
|
Secondary Objective: - To evaluate each of the components of the composite efficacy endpoint - To evaluate the time to event and severity of BPAR - To evaluate incidence of biopsy proven antibody mediated rejection - To evaluate the Incidence/progression of chronic allograft nephropathy (Interstitial Fibrosis and Tubular Atrophy IF/TA) by histopathology. - To evaluate growth and development, including linear growth, sexual maturation, hormonal gonadal axis (estradiol, testosterone, LH, FSH, inhibin B), TSH, T3 and T4
|
Main Objective: - To estimate the rate of the composite efficacy endpoint of BPAR, graft loss or death at 12 months post transplantation in primary paediatric kidney transplant recipients converted at 4-6 weeks post-transplantation from MMF + standard TAC regimen and steroids, to everolimus + reduced dose TAC regimen and steroid withdrawal at 6 months, versus continuation of MMF + standard TAC regimen and steroids. - To evaluate renal function assessed by Glomerular Filtration Rate (eGFR) estimated by the Schwartz formula (abbreviated) at month 12.
|
Timepoint(s) of evaluation of this end point: Month 12 after transplantation.
|
Secondary Outcome(s)
|
Secondary end point(s): 1- Components of the composite efficacy endpoint;
2- Incidences of biopsy proven antibody mediated rejection
3- Incidence/progression of chronic allograft nephropathy (interstitial fibrosis and tubular atrophy, IF/TA);
4- Safety (evolution of renal function over time, incidence of proteinuria, the frequency of drug-related side effects (CNI-related, mTOR-inhibitor-specific or MMF-class effects), assessment of growth and development, the frequency of AEs/Infections, SAEs.
|
Timepoint(s) of evaluation of this end point: Month 12 and 36 after transplantation.
|
Secondary ID(s)
|
2010-024381-21-HU
|
CRAD001A2314
|
Source(s) of Monetary Support
|
Novartis Pharma Services AG
|
Ethics review
|
Status: Approved
Approval date: 01/12/2011
Contact:
|
|